We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GAO: FDA Must Clarify How Expanded Access Data Will Be Used
GAO: FDA Must Clarify How Expanded Access Data Will Be Used
The FDA needs to clearly communicate to drugmakers how the agency will use adverse event data gleaned through the expanded access use process, according to a new GAO report.